Redeye provides an update following Neola Medical’s Q3 2025 report. The quarterly figures showed no major surprises. However, preliminary results from the Swedish clinical pilot study indicate that the Neola device requires improvements, causing a delay in the upcoming US study and subsequent market launch. We have revised our estimates to reflect this delay, resulting in an updated fair value range.
LÄS MER
